Results 181 to 190 of about 32,756 (253)

Glucagon-like Peptide-1 Receptor Agonists in Liver Transplant Recipients: A Retrospective Cohort Study. [PDF]

Transplant Direct
Sheashaa H, Ibrahim R, Elshaer A, Pham HN, Mouhaffel R, Habib E, Abdelnabi M, Farina JM, Lester SJ, Simper D, Alsidawi S, Steidley ED, Aqel BA, Barnhill M, Kim WR, Ayoub C, Arsanjani R.   +16 more
europepmc   +1 more source

Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities. [PDF]

Front Immunol
Ciancio G, Maranini B, Sandri G, Amati G, Bortoluzzi A, Silvagni E, Govoni M, Giuggioli D.   +7 more
europepmc   +1 more source

Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Orforglipron is a novel small‐molecule, once daily oral non‐peptide GLP‐1 receptor agonist. The hepatic safety profile in adults with obesity or overweight and/or type 2 diabetes (T2D) across seven orforglipron Phase 3 clinical trials was assessed.
Sean Wharton, Adam Stefanski, Jiaxun Chen, Girish Rao, Elvis Asare Twum, Max Denning   +5 more
wiley   +1 more source

Comparison of Perioperative Glycemic Control in Patients Continuing Versus Temporarily Holding Glucagon-Like Peptide-1 Receptor Agonists or Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists Preoperatively. [PDF]

AACE Endocrinol Diabetes
Trykall CC, Hill SB, James AM, Bagnola AJ, Wyne KL, Handley D, Brower KI.   +6 more
europepmc   +1 more source

Prevalence of Obesity and Related Conditions and GLP‐1 Use in Medicare Fee‐for‐Service Beneficiaries

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study estimated the number and percentage of Medicare fee‐for‐service (FFS) beneficiaries who use GLP‐1 RAs, are currently eligible or could become eligible if ongoing‐trial indications receive approval and coverage. Materials and Methods This retrospective cohort study used Medicare enrolment and claims data, representing 100% of ...
Sonia Kim, Andrea Barthel, Marlene Smurzynski, Joanna MacEwan   +3 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists for Bile Acid Diarrhea: Emerging Evidence and Clinical Implications. [PDF]

Cureus
Omeludike EK, Nwabueze CO, Ubah N, Okeke N, Aregbesola E, Onyiaorah CR, Igbokwe MA, Gujral M, Lawal RA, Akande YF.   +9 more
europepmc   +1 more source

Tirzepatide for Excess Weight in Adults With Type 1 Diabetes Using MiniMed 780G

Diabetes, Obesity and Metabolism, EarlyView.
Michelantonio De Fano, Rachele Tortoriello, Stefania Rucco, Sofia Corio, Marcello Manco, Edoardo Guerrini, Francesca Porcellati   +6 more
wiley   +1 more source

Potential Antiarrhythmic Mechanisms of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs). [PDF]

Drug Des Devel Ther
Li J, Fu K, Zhao J, Zou Y, Li L, Huang Q, Long L, Ou X, Lei M, Zhang C, Tan X, Chen T.   +11 more
europepmc   +1 more source

Cardiovascular Efficacy of GLP‐1 Receptor Agonists by Kidney Function: An Updated Meta‐Analysis of Randomized Trials Including the SOUL Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the cardiovascular efficacy and absolute benefit of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) by baseline estimated glomerular filtration rate (eGFR). Materials and Methods PubMed and EMBASE were searched to 29 April 2026 for randomized placebo‐controlled trials of GLP‐1RAs in adults with type 2 diabetes or ...
Masashi Hasebe, Chen‐Yang Su, Daisuke Yabe, Satoshi Yoshiji   +3 more
wiley   +1 more source

Corrigendum to: The Short and Sweet on Sodium-Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure. [PDF]

US Cardiol
Batista JL, Makuvire T, Davis JD, Carbone S.   +3 more
europepmc   +1 more source